ADMA Biologics (ADMA)
(Delayed Data from NSDQ)
$15.78 USD
-0.34 (-2.11%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $15.80 +0.02 (0.13%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.78 USD
-0.34 (-2.11%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $15.80 +0.02 (0.13%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Zacks News
Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Rocket Pharmaceuticals' (RCKT) fourth-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.
Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y
by Zacks Equity Research
Fate Therapeutics (FATE) reports encouraging fourth-quarter results as loss narrows year over year due to lower operating expenses.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -10.61% and 0.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Bausch (BHC) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Bausch (BHC) fourth-quarter earnings and sales beat their respective estimates. The guidance for 2024 looks encouraging.
Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Intra-Cellular (ITCI) reports mixed fourth-quarter 2023 results despite Caplyta sales rising year over year on the back of increasing prescription trends.
Adma Biologics (ADMA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Adma Biologics (ADMA) closed at $5.26 in the latest trading session, marking a +1.54% move from the prior day.
CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock Up
by Zacks Equity Research
CRISPR (CRSP) gains on encouraging fourth-quarter 2023 results, beating both earnings and revenue estimates on the back of collaboration revenues received from Vertex.
Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $5.18, denoting a +0.58% change from the preceding trading day.
Bristol Myers' (BMY) Krazati sNDA for CRC Gets Priority Review
by Zacks Equity Research
Bristol Myers (BMY) announces FDA's acceptance of the sNDA seeking approval for the Krazati/Erbitux combo therapy to treat CRC patients. A final decision is expected on Jun 21, 2024.
Pfizer's (PFE) Ulcerative Colitis Pill Velsipity Gets EU Nod
by Zacks Equity Research
The approval for Pfizer's (PFE) Velsipity (etrasimod) is based on data from two pivotal phase III studies, ELEVATE UC 52 and ELEVATE 12.
Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up
by Zacks Equity Research
Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.
Blueprint (BPMC) Q4 Earnings Beat, Stock Up as Ayvakit Shines
by Zacks Equity Research
Blueprint (BPMC) climbs 14% on better-than-expected fourth-quarter 2023 results, driven by increased Ayvakit sales following the drug's label expansion for the ISM indication.
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
Adma Biologics (ADMA) closed at $5.40 in the latest trading session, marking a +1.31% move from the prior day.
Here's Why Momentum in Adma Biologics (ADMA) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Zoetis' (ZTS) Q4 Earnings Miss Expectations, Sales Beat
by Zacks Equity Research
Zoetis (ZTS) reports mixed fourth-quarter results, wherein earnings miss estimates while revenues beat the same.
Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) gains 3% on encouraging fiscal third-quarter 2024 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.
New Strong Buy Stocks for February 13th
by Zacks Equity Research
IKT, ETRN, ADMA, AFRM and ORC have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2023.
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the fourth quarter of 2023, partially offset by declining livestock product sales.
3 Medical Stocks to Buy as the Sector Continues to Grow
by Abhinab Dasgupta
HCA Healthcare (HCA), ADMA Biologics (ADMA) and Exelixis (EXEL) are three medical stocks that you can look into as the sector continues to sustain its end-of-the-year momentum.
Adma Biologics (ADMA) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Adma Biologics (ADMA) closed at $5.18 in the latest trading session, marking a -1.71% move from the prior day.
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Does Adma Biologics (ADMA) Have the Potential to Rally 31.55% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 31.6% in Adma Biologics (ADMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Adma Biologics (ADMA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Adma Biologics (ADMA) closed the most recent trading day at $5.23, moving -1.32% from the previous trading session.
Bristol Myers' (BMY) sBLAs for Breyanzi Get FDA Priority Tag
by Zacks Equity Research
Bristol Myers' (BMY) two sBLAs for Breyanzi in relapsed/refractory follicular lymphoma and relapsed/refractory mantle cell lymphoma receive FDA acceptance and priority review.